Spina Bifida Treatment Market are driven by Growing Disability Rates
Spina bifida is a birth defect that occurs when the spine and spinal cord do not properly develop in utero, leaving part of the spinal cord exposed. It can cause mild to severe physical disability depending on which parts of the spinal cord are affected. Spina bifida treatments during fetal development aim to repair the exposed part of the spinal cord before birth. Fetal surgery techniques involve opening the uterus and closing the opening in the spine while the fetus is still in utero between 19-25 weeks of gestation. This approach has advantages over postnatal repair as it prevents damage to the spinal cord from exposure to amniotic fluid before birth.
The Spina Bifida In-Utero - Market is estimated to be valued at USD 2.71 billion in 2024 and is expected to reach USD 4.89 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
Key players operating in the Spina Bifida In-Utero market are Johnson & Johnson, Medtronic, Boston Scientific Corporation and Stryker Corporation. Over the past decade, fetal surgeries to repair spina bifida in utero have increased significantly owing to advancements in minimally invasive techniques and growing acceptance among expecting parents and physicians. While the U.S currently dominates the Spina Bifida In-Utero Market, other regions like Europe and Asia Pacific are witnessing rising adoption.
Get More Insights On-Spina Bifida In-Utero Market
Get this Report in Japanese Language: 子宮内二分脊椎市場
Get this Report in Korean Language: 자궁 내 척추이분증 시장
Explore More Related Articles- The Rising Dominance of Global Fashion Ecommerce
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian